

# Tim L Jansen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8629719/publications.pdf>

Version: 2024-02-01

96  
papers

6,014  
citations

125106

35  
h-index

81351

76  
g-index

98  
all docs

98  
docs citations

98  
times ranked

5710  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658.	1.5	23
2	Outcomes of Care Among Patients With Gout in Europe: A Cross-sectional Survey. <i>Journal of Rheumatology</i> , 2022, 49, 312-319.	1.0	3
3	Erosive Hand OsteoArthritis (EHOA): analysis of consecutive patients presenting with EHOA in a hospital-based rheumatology practice and its implications for an upcoming interventional study. <i>Clinical Rheumatology</i> , 2022, 41, 1833-1841.	1.0	2
4	Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 95.	1.5	2
5	Sex Differences in the Clinical Profile Among Patients With Gout: Cross-sectional Analyses of an Observational Study. <i>Journal of Rheumatology</i> , 2021, 48, 286-292.	1.0	19
6	Hughes-Stovin syndrome (HSS): current status and future perspectives. <i>Clinical Rheumatology</i> , 2021, 40, 4787-4789.	1.0	7
7	Comparative Study of Real-life Management Strategies in Gout: Data From Two Protocolized Gout Clinics. <i>Arthritis Care and Research</i> , 2020, 72, 1169-1176.	1.5	4
8	Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e270-e280.	2.2	130
9	Lessons and pitfalls from the 2020 Gout Clinical Practice Guideline presented in Atlanta at the ACR 2019. <i>Clinical Rheumatology</i> , 2020, 39, 2011-2016.	1.0	0
10	Clinical image. <i>Clinical Rheumatology</i> , 2020, 39, 2235-2236.	1.0	1
11	Understanding the patient voice in gout: a quantitative study conducted in Europe. <i>BJGP Open</i> , 2020, 4, bjgpopen20X101003.	0.9	8
12	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. <i>BMC Rheumatology</i> , 2019, 3, 3.	0.6	4
13	Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. <i>Clinical Rheumatology</i> , 2019, 38, 1385-1391.	1.0	39
14	Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy. <i>Rheumatology and Therapy</i> , 2019, 6, 101-108.	1.1	4
15	Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. <i>Clinical Rheumatology</i> , 2019, 38, 263-265.	1.0	11
16	International position paper on the appropriate use of uricosurics with the introduction of lesinurad. <i>Clinical Rheumatology</i> , 2018, 37, 3159-3165.	1.0	15
17	Measuring Disease Exacerbation and Flares in Rheumatoid Arthritis: Comparison of Commonly Used Disease Activity Indices and Individual Measures. <i>Journal of Rheumatology</i> , 2017, 44, 1118-1124.	1.0	2
18	Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors. <i>Rheumatology</i> , 2017, 56, 1560-1565.	0.9	19

#	ARTICLE	IF	CITATIONS
19	2016 updated EULAR evidence-based recommendations for the management of gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 29-42.	0.5	1,096
20	The American College of Physicians and the 2017 guideline for the management of acute and recurrent gout: treat to avoiding symptoms versus treat to target. <i>Clinical Rheumatology</i> , 2017, 36, 2399-2402.	1.0	10
21	Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients. <i>Rheumatology International</i> , 2017, 37, 1435-1440.	1.5	14
22	Crystal identification of synovial fluid aspiration by polarized light microscopy. An online test suggesting that our traditional rheumatologic competence needs renewed attention and training. <i>Clinical Rheumatology</i> , 2017, 36, 641-647.	1.0	41
23	Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. <i>Arthritis and Rheumatology</i> , 2017, 69, 429-438.	2.9	93
24	Performance of classification criteria for gout in early and established disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 178-182.	0.5	36
25	Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 755-762.	0.5	202
26	Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. <i>Journal of Rheumatology</i> , 2016, 43, 150-153.	1.0	25
27	Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 593-600.	0.5	90
28	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2557-2568.	2.9	393
29	Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 134.	1.6	57
30	Personalizing Treatment Targets in Rheumatoid Arthritis by Using a Simple Prediction Model. <i>Journal of Rheumatology</i> , 2015, 42, 398-404.	1.0	11
31	Gout: cartoonized and bagatellized and still left untreated. Time to change. <i>Clinical Rheumatology</i> , 2015, 34, 1317-1319.	1.0	1
32	Rational pharmacotherapy (RPT) in goutology: Define the serum uric acid target & treat-to-target patient cohort and review on urate lowering therapy (ULT) applying synthetic drugs. <i>Joint Bone Spine</i> , 2015, 82, 225-229.	0.8	6
33	Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout. <i>Arthritis Care and Research</i> , 2015, 67, 1304-1315.	1.5	101
34	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1789-1798.	0.5	545
35	Imaging modalities for the classification of gout: systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1868-1874.	0.5	145
36	Functionally active NKG2A-expressing natural killer cells are elevated in rheumatoid arthritis patients compared to psoriatic arthritis patients and healthy donors. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 795-804.	0.4	3

#	ARTICLE	IF	CITATIONS
37	Association of the TNF- $\alpha$ G-308A polymorphism with TNF-inhibitor response in sarcoidosis. <i>European Respiratory Journal</i> , 2014, 43, 1730-1739.	3.1	81
38	Treat to target in gout by combining two modes of action. <i>Rheumatology</i> , 2014, 53, 2131-2133.	0.9	4
39	Pulmonology meets rheumatology in sarcoidosis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 276-284.	2.0	14
40	Additive value for ultrasonographic signal in a screening algorithm for patients presenting with acute mono-oligoarthritis in whom gout is suspected. <i>Clinical Rheumatology</i> , 2014, 33, 555-559.	1.0	48
41	Improving cardiovascular and renal outcomes in gout: what should we target?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 654-661.	3.5	169
42	New gout test: enhanced ex vivo cytokine production from PBMCs in common gout patients and a gout patient with Kearns-Sayre syndrome. <i>Clinical Rheumatology</i> , 2014, 33, 1341-1346.	1.0	8
43	Practical eminence and experience-based recommendations for use of TNF- $\alpha$ inhibitors in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014, 31, 91-107.	0.2	69
44	New classification criteria for gout: a framework for progress. <i>Rheumatology</i> , 2013, 52, 1748-1753.	0.9	37
45	Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1375-1381.	0.5	94
46	Can response duration after the first rituximab treatment be used in timing of rituximab retreatment?. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 251-252.	0.6	2
47	THU0168...How Low Should You Go? Towards Personalized Treatment Targets for Disease Activity in RA. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A220.2-A220.	0.5	0
48	Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 545-561.	1.2	145
49	AB0629...A critical appraisal of the competence of crystal identification by rheumatologists.. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A981.3-A982.	0.5	6
50	Gout: why is this curable disease so seldom cured?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1765-1770.	0.5	228
51	Rheumatology meets hepatology in 2012: a clinician's guideline for TNF inhibitors in hepatitis B/C virus carriers. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 391-393.	1.4	5
52	Rheumatology meets radiology in the hot soup of Gutta. <i>Arthritis Research and Therapy</i> , 2012, 14, 126.	1.6	3
53	EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 571-575.	0.5	193
54	European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 563-570.	0.5	418

#	ARTICLE	IF	CITATIONS
55	Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. <i>Clinical Rheumatology</i> , 2011, 30, 293-300.	1.0	29
56	The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 715-726.	1.0	17
57	Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 877-878.	0.5	32
58	Effectiveness of a Third Tumor Necrosis Factor- $\alpha$ -blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 2355-2361.	1.0	23
59	Therapeutic consequences of crystals in the synovial fluid: a review for clinicians. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 1032-9.	0.4	9
60	International position paper on febuxostat. <i>Clinical Rheumatology</i> , 2010, 29, 835-840.	1.0	49
61	Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. <i>Arthritis Care and Research</i> , 2010, 62, 1335-1341.	1.5	34
62	Genetic Variants in Toll-Like Receptors Are Not Associated with Rheumatoid Arthritis Susceptibility or Anti-Tumour Necrosis Factor Treatment Outcome. <i>PLoS ONE</i> , 2010, 5, e14326.	1.1	24
63	New advances in the treatment of gout: review of pegloticase. <i>Therapeutics and Clinical Risk Management</i> , 2010, Volume 6, 543-550.	0.9	39
64	Management of hyperuricemia in gout: focus on febuxostat. <i>Clinical Interventions in Aging</i> , 2010, 5, 7.	1.3	45
65	When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers?. <i>Arthritis Research and Therapy</i> , 2010, 12, 103.	1.6	10
66	International position paper on febuxostat. <i>Clinical Rheumatology</i> , 2010, 29, 835.	1.0	3
67	Gout. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2009, 106, 549-55.	0.6	71
68	Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1470-1473.	0.5	78
69	Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 844-849.	0.5	16
70	Borrelial fasciitis: as yet insufficient proof for a distinct entity. <i>Rheumatology International</i> , 2009, 29, 1385-1388.	1.5	0
71	The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 2171-2177.	1.0	48
72	The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1473-1478.	0.5	174

#	ARTICLE	IF	CITATIONS
73	The effectiveness and medication costs of three anti-tumour necrosis factor $\hat{A}$ agents in the treatment of rheumatoid arthritis from prospective clinical practice data. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1229-1234.	0.5	105
74	Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. <i>Clinical Rheumatology</i> , 2007, 26, 1459-1465.	1.0	78
75	Medical Mystery: Arthritis $\hat{e}$ ” The Answer. <i>New England Journal of Medicine</i> , 2006, 355, 421-422.	13.9	5
76	A Medical Mystery $\hat{e}$ ” Arthritis. <i>New England Journal of Medicine</i> , 2006, 354, 2375-2375.	13.9	7
77	Leflunomide for the Treatment of Rheumatoid Arthritis in Clinical Practice. <i>Drug Safety</i> , 2004, 27, 345-352.	1.4	65
78	Two years of penicillin prophylaxis is sufficient to prevent clinically evident carditis in poststreptococcal reactive arthritis. <i>Journal of Internal Medicine</i> , 2001, 250, 449-452.	2.7	1
79	Glucocorticosteroids in the management of rheumatoid arthritis. <i>Rheumatology</i> , 1999, 38, 6-12.	0.9	58
80	A clinical and serological comparison of group A versus non-group A streptococcal reactive arthritis and throat culture negative cases of post-streptococcal reactive arthritis. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 410-414.	0.5	21
81	Post $\hat{e}$ streptococcal reactive arthritis: a clinical and serological description, revealing its distinction from acute rheumatic fever. <i>Journal of Internal Medicine</i> , 1999, 245, 261-267.	2.7	59
82	Impairment of quality of life: rheumatoid arthritis versus sarcoidosis. <i>Netherlands Journal of Medicine</i> , 1999, 54, 86-95.	0.6	41
83	Post-streptococcal reactive myalgia: a novel syndrome secondary to infection with group A or G streptococci. <i>British Journal of Rheumatology</i> , 1998, 37, 1343-1348.	2.5	12
84	Reactive arthritis associated with group C and group G beta-hemolytic streptococci. <i>Journal of Rheumatology</i> , 1998, 25, 1126-30.	1.0	21
85	Dermatomyositis with subclinical myositis and spontaneous pneumomediastinum with pneumothorax: case report and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 1998, 16, 733-5.	0.4	25
86	The clinical spectrum of post-streptococcal syndromes with arthritis in children. <i>Clinical and Experimental Rheumatology</i> , 1998, 16, 750-2.	0.4	13
87	Effect of Atrial Natriuretic Factor on Skin Microcirculation Versus Skeletal Muscle Blood Flow. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 27, 303-306.	0.8	8
88	Atrial Natriuretic Factor Potentiates the Human Forearm Vasoconstrictor Response to Sympathetic Stimulation. <i>Clinical Science</i> , 1994, 86, 275-283.	1.8	6
89	Opportunistic Infections and Profound CD8+ T Lymphocytopenia in Mixed Connective Tissue Disease. <i>Journal of Infectious Diseases</i> , 1993, 168, 1333-1334.	1.9	1
90	Impaired Vasodilator Response to Atrial Natriuretic Factor in IDDM. <i>Diabetes</i> , 1993, 42, 1454-1461.	0.3	21

#	ARTICLE	IF	CITATIONS
91	Comparison of Cyclic Guanosine Monophosphate Response to Infusion of Atrial Natriuretic Peptide in Young and Elderly Subjects. <i>Journal of the American Geriatrics Society</i> , 1993, 41, 1241-1244.	1.3	1
92	Kinetics of atrial natriuretic peptide in young and elderly subjects. <i>European Journal of Clinical Pharmacology</i> , 1992, 42, 449-452.	0.8	16
93	Attenuated forearm vasodilator response to atrial natriuretic factor in the elderly.. <i>Hypertension</i> , 1991, 18, 640-647.	1.3	12
94	Age-Dependent Vasodilation of the Skin Microcirculation by Atrial Natriuretic Factor. <i>Journal of Cardiovascular Pharmacology</i> , 1991, 18, 622-630.	0.8	6
95	Hemodynamic effects of atrial natriuretic factor in young and elderly subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 179-188.	2.3	18
96	A comparison of the vasodilator responses to atrial peptides in the pulmonary and renal arteries of the pig <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 1987, 91, 687-691.	2.7	27